Basson Abigail Raffner, Rodriguez-Palacios Alexander, Cominelli Fabio
Division of Gastroenterology and Liver Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
Front Nutr. 2021 Sep 24;8:746247. doi: 10.3389/fnut.2021.746247. eCollection 2021.
Since the introduction of artificial sweeteners (AS) to the North American market in the 1950s, a growing number of epidemiological and animal studies have suggested that AS may induce changes in gut bacteria and gut wall immune reactivity, which could negatively affect individuals with or susceptible to chronic inflammatory conditions such as inflammatory bowel disease (IBD), a disorder that has been growing exponentially in westernized countries. This review summarizes the history of current FDA-approved AS and their chemical composition, metabolism, and bacterial utilization, and provides a scoping overview of the disease mechanisms associated with the induction or prevention of inflammation in IBD. We provide a general outlook on areas that have been both largely and scarcely studied, emerging concepts using silica, and describe the effects of AS on acute and chronic forms of intestinal inflammation.
自20世纪50年代人工甜味剂(AS)引入北美市场以来,越来越多的流行病学和动物研究表明,AS可能会引起肠道细菌和肠壁免疫反应性的变化,这可能会对患有慢性炎症性疾病(如炎症性肠病,IBD)或易患此类疾病的个体产生负面影响,IBD在西方国家的发病率呈指数级增长。本综述总结了目前美国食品药品监督管理局(FDA)批准的AS的历史及其化学成分、代谢和细菌利用情况,并对与IBD炎症的诱导或预防相关的疾病机制进行了概述。我们对研究较多和较少的领域、使用二氧化硅的新兴概念提供了总体展望,并描述了AS对急性和慢性肠道炎症形式的影响。